Tango Therapeutics, Inc. (TNGX): Price and Financial Metrics
TNGX Price/Volume Stats
| Current price | $4.26 | 52-week high | $12.02 |
| Prev. close | $3.51 | 52-week low | $1.03 |
| Day low | $3.58 | Volume | 9,169,285 |
| Day high | $4.71 | Avg. volume | 1,524,030 |
| 50-day MA | $1.69 | Dividend yield | N/A |
| 200-day MA | $4.04 | Market Cap | 461.76M |
TNGX Stock Price Chart Interactive Chart >
Tango Therapeutics, Inc. (TNGX) Company Bio
Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
TNGX Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TNGX Price Returns
| 1-mo | 270.43% |
| 3-mo | 111.94% |
| 6-mo | 25.85% |
| 1-year | -40.83% |
| 3-year | -27.67% |
| 5-year | N/A |
| YTD | 37.86% |
| 2024 | -68.79% |
| 2023 | 36.55% |
| 2022 | -33.73% |
| 2021 | -4.37% |
| 2020 | N/A |